Tgfbr2 (transforming growth factor, beta receptor 2) - Rat Genome Database

Send us a Message



Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   
Gene: Tgfbr2 (transforming growth factor, beta receptor 2) Rattus norvegicus
Analyze
Symbol: Tgfbr2
Name: transforming growth factor, beta receptor 2
RGD ID: 69651
Description: Enables mitogen-activated protein kinase kinase kinase binding activity and transforming growth factor beta receptor activity, type II. Involved in several processes, including negative regulation of cardiac muscle cell proliferation; positive regulation of skeletal muscle tissue regeneration; and transmembrane receptor protein serine/threonine kinase signaling pathway. Located in caveola; cell surface; and cytosol. Is integral component of plasma membrane. Used to study membranoproliferative glomerulonephritis. Biomarker of artery disease (multiple); hepatobiliary system cancer (multiple); kidney disease; pulmonary fibrosis; and type 2 diabetes mellitus. Human ortholog(s) of this gene implicated in Loeys-Dietz syndrome 2; Marfan syndrome; gastrointestinal system cancer (multiple); hereditary nonpolyposis colorectal cancer type 6; and pancreatic cancer. Orthologous to human TGFBR2 (transforming growth factor beta receptor 2); PARTICIPATES IN transforming growth factor-beta Smad dependent signaling pathway; altered transforming growth factor-beta Smad dependent signaling pathway; colorectal cancer pathway; INTERACTS WITH (S)-nicotine; 17beta-estradiol; 2,3,7,8-tetrachlorodibenzodioxine.
Type: protein-coding
RefSeq Status: VALIDATED
Previously known as: tbetaR-II; TGF-beta 2; TGF-beta receptor type II; TGF-beta receptor type-2; TGF-beta type II receptor; Tgfbr2T; TGFR-2; transforming growth factor beta receptor 2; transforming growth factor beta receptor type II; transforming growth factor beta, receptor 2; transforming growth factor, beta receptor II; transforming growth factor, beta receptor IIT; transforming growth factor-b type II receptor; transforming growth factor-beta receptor type II; transforming growth factor-beta type II receptor
RGD Orthologs
Human
Mouse
Chinchilla
Bonobo
Dog
Squirrel
Pig
Green Monkey
Naked Mole-Rat
Alliance Genes
More Info more info ...
Allele / Splice: Tgfbr2m2Mcwi   Tgfbr2m1Mcwi  
Genetic Models: FHH-Tgfbr2m2Mcwi BN-Tgfbr2m1Mcwi
Latest Assembly: mRatBN7.2 - mRatBN7.2 Assembly
Position:
Rat AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
mRatBN7.28115,794,537 - 115,883,615 (-)NCBImRatBN7.2
mRatBN7.2 Ensembl8115,794,537 - 115,883,228 (-)Ensembl
Rnor_6.08124,310,288 - 124,399,345 (-)NCBIRnor6.0Rnor_6.0rn6Rnor6.0
Rnor_6.0 Ensembl8124,312,754 - 124,399,494 (-)EnsemblRnor6.0rn6Rnor6.0
Rnor_5.08123,585,765 - 123,671,209 (-)NCBIRnor5.0Rnor_5.0rn5Rnor5.0
RGSC_v3.48120,593,595 - 120,680,453 (-)NCBIRGSC3.4rn4RGSC3.4
RGSC_v3.18120,613,331 - 120,700,190 (-)NCBI
Celera8115,012,175 - 115,096,500 (-)NCBICelera
Cytogenetic Map8q32NCBI
JBrowse: View Region in Genome Browser (JBrowse)
Model


Disease Annotations     Click to see Annotation Detail View
Aneurysm  (ISO)
aortic aneurysm  (ISO)
arteriosclerosis  (ISO)
bone disease  (ISO)
Bone Fractures  (ISO)
Bone Neoplasms  (ISO)
Brain Neoplasms  (ISO)
carcinoma  (ISO)
cholangiocarcinoma  (IEP)
cleft soft palate  (ISS)
colon cancer  (ISO)
Colonic Neoplasms  (ISO)
colorectal cancer  (ISO)
connective tissue disease  (ISO)
Craniofacial Abnormalities  (ISO)
Diabetic Nephropathies  (ISO)
DiGeorge syndrome  (ISS)
Dissecting Aneurysm  (ISO)
esophageal cancer  (ISO)
Esophageal Neoplasms  (ISO)
Experimental Arthritis  (IEP)
Experimental Liver Cirrhosis  (IDA,IEP,ISO)
Eye Abnormalities  (ISO)
Familial Thoracic Aortic Aneurysm 1  (ISO)
Fatigue  (ISO)
gastrointestinal stromal tumor  (ISO)
genetic disease  (ISO)
hepatoblastoma  (ISO)
hepatocellular carcinoma  (IEP)
hereditary nonpolyposis colorectal cancer type 6  (ISO)
Hyperplasia  (IEP)
inguinal hernia  (ISO)
kidney disease  (IEP)
Loeys-Dietz syndrome  (ISO)
Loeys-Dietz syndrome 1  (ISO)
Loeys-Dietz syndrome 2  (ISO)
Loeys-Dietz Syndrome, Type 1b  (ISO)
Lung Neoplasms  (ISO)
Lynch syndrome  (ISO)
Mammary Neoplasms, Experimental  (ISO)
Marfan syndrome  (ISO)
Marfan Syndrome Type 2  (ISO)
Marfanoid Hypermobility Syndrome  (ISO)
membranoproliferative glomerulonephritis  (IDA)
Microsatellite Instability  (ISO)
migraine  (ISO)
multiple acyl-CoA dehydrogenase deficiency  (ISO)
myocardial infarction  (IEP)
Neoplasm Metastasis  (ISO)
pancreatic cancer  (ISO)
pancreatic ductal carcinoma  (ISO)
prostate cancer  (ISS)
Prostatic Neoplasms  (ISO)
pulmonary fibrosis  (IEP)
pulmonary hypertension  (IEP)
Radiation Injuries  (IDA)
Reperfusion Injury  (IEP)
thoracic aortic aneurysm  (ISO)
type 2 diabetes mellitus  (IEP)
vasculogenic impotence  (ISO)
Wolff-Parkinson-White syndrome  (ISO)

Gene-Chemical Interaction Annotations     Click to see Annotation Detail View
(S)-amphetamine  (ISO)
(S)-nicotine  (EXP)
1,2-dimethylhydrazine  (ISO)
17alpha-ethynylestradiol  (ISO)
17beta-estradiol  (EXP,ISO)
2,2',4,4',5,5'-hexachlorobiphenyl  (ISO)
2,3,7,8-tetrachlorodibenzodioxine  (EXP,ISO)
2-butoxyethanol  (ISO)
2-nitrotoluene  (EXP)
3,4-methylenedioxymethamphetamine  (ISO)
3-isobutyl-1-methyl-7H-xanthine  (ISO)
3-methyl-3H-imidazo[4,5-f]quinolin-2-amine  (ISO)
4,4'-diaminodiphenylmethane  (ISO)
4,4'-sulfonyldiphenol  (ISO)
4-(ethoxymethylene)-2-phenyloxazol-5-one  (ISO)
4-nitrophenol  (ISO)
4-vinylcyclohexene dioxide  (ISO)
5-aza-2'-deoxycytidine  (EXP,ISO)
8-Br-cAMP  (ISO)
acetaldehyde  (EXP)
acetamide  (EXP)
acteoside  (ISO)
aflatoxin B1  (ISO)
Aflatoxin B2 alpha  (ISO)
aldehydo-D-glucose  (ISO)
all-trans-retinoic acid  (EXP,ISO)
all-trans-retinol  (ISO)
aluminium oxide  (ISO)
ammonium chloride  (EXP)
antirheumatic drug  (ISO)
arsane  (ISO)
arsenic atom  (ISO)
arsenite(3-)  (ISO)
arsenous acid  (ISO)
asbestos  (ISO)
avobenzone  (ISO)
azoxystrobin  (ISO)
benzo[a]pyrene  (ISO)
benzo[a]pyrene diol epoxide I  (ISO)
benzo[b]fluoranthene  (ISO)
benzo[e]pyrene  (ISO)
bis(2-ethylhexyl) phthalate  (ISO)
bisphenol A  (EXP,ISO)
bisphenol F  (ISO)
bleomycin A2  (ISO)
bromochloroacetic acid  (EXP)
butan-1-ol  (ISO)
cadmium atom  (ISO)
cadmium dichloride  (ISO)
calciol  (ISO)
calcitriol  (ISO)
Candesartan cilexetil  (EXP)
cannabidiol  (EXP)
carbamazepine  (ISO)
carbon nanotube  (ISO)
CGP 52608  (ISO)
chloropicrin  (ISO)
chromium(6+)  (ISO)
cisplatin  (ISO)
cobalt dichloride  (ISO)
copper atom  (ISO)
copper(0)  (ISO)
copper(II) sulfate  (ISO)
curcumin  (EXP)
cycloheximide  (ISO)
cyclophosphamide  (ISO)
cyclosporin A  (EXP,ISO)
cyproconazole  (ISO)
D-glucose  (ISO)
deguelin  (ISO)
dexamethasone  (ISO)
diarsenic trioxide  (ISO)
diazepam  (ISO)
diethylstilbestrol  (ISO)
dimethylarsinic acid  (EXP)
dioxygen  (ISO)
diuron  (EXP)
doxorubicin  (ISO)
doxycycline  (ISO)
epoxiconazole  (ISO)
ethanol  (ISO)
folic acid  (ISO)
furosemide  (EXP)
galangin  (ISO)
genistein  (EXP)
gentamycin  (EXP)
glucose  (ISO)
glycyrrhizinic acid  (ISO)
glyphosate  (ISO)
hexachlorobenzene  (ISO)
hydrogen peroxide  (ISO)
indometacin  (ISO)
Isoangustone A  (ISO)
isobutanol  (ISO)
isoprenaline  (ISO)
isotretinoin  (ISO)
L-cysteine  (EXP)
L-methionine  (EXP)
leflunomide  (ISO)
lipopolysaccharide  (EXP)
lithium chloride  (ISO)
lithocholic acid  (ISO)
medroxyprogesterone acetate  (ISO)
menadione  (ISO)
methamphetamine  (EXP,ISO)
methapyrilene  (ISO)
methotrexate  (ISO)
methoxychlor  (EXP)
methyl beta-cyclodextrin  (ISO)
methylarsonic acid  (EXP)
Methylazoxymethanol acetate  (EXP)
methylmercury chloride  (ISO)
methylseleninic acid  (ISO)
N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine  (ISO)
N-acetyl-L-cysteine  (EXP)
N-nitrosodiethylamine  (EXP,ISO)
N-nitrosodimethylamine  (EXP)
N-Vinyl-2-pyrrolidone  (EXP)
nickel sulfate  (ISO)
nicotine  (EXP)
nitrofen  (EXP)
osthole  (ISO)
oxalic acid  (ISO)
paracetamol  (EXP,ISO)
paraquat  (EXP)
patulin  (EXP)
perfluorooctanoic acid  (ISO)
perindopril  (EXP)
phenobarbital  (EXP,ISO)
phenylephrine  (EXP)
picoxystrobin  (ISO)
pirinixic acid  (EXP,ISO)
platycodin D  (ISO)
potassium chromate  (ISO)
progesterone  (ISO)
propiconazole  (ISO)
prostaglandin E2  (ISO)
quercetin  (ISO)
raloxifene  (ISO)
resveratrol  (ISO)
rotenone  (EXP,ISO)
S-butyl-DL-homocysteine (S,R)-sulfoximine  (EXP)
salvianolic acid B  (EXP)
SB 431542  (ISO)
serpentine asbestos  (ISO)
simvastatin  (EXP,ISO)
sodium arsenite  (EXP,ISO)
sodium fluoride  (ISO)
streptozocin  (ISO)
succimer  (ISO)
tacrolimus hydrate  (EXP)
testosterone  (ISO)
tetrachloromethane  (EXP,ISO)
thioacetamide  (EXP)
tipifarnib  (EXP)
tolfenamic acid  (ISO)
toluene 2,4-diisocyanate  (ISO)
torcetrapib  (ISO)
trichostatin A  (ISO)
troglitazone  (ISO)
valproic acid  (ISO)
valsartan  (EXP)
vancomycin  (ISO)
vinclozolin  (EXP)

Gene Ontology Annotations     Click to see Annotation Detail View

Biological Process
activation of protein kinase activity  (ISO)
activin receptor signaling pathway  (IEA)
aging  (IEP)
animal organ morphogenesis  (IMP)
animal organ regeneration  (IEP)
apoptotic process  (ISO)
atrioventricular valve morphogenesis  (ISO)
brain development  (ISO)
branching involved in blood vessel morphogenesis  (ISO)
bronchus development  (ISO)
bronchus morphogenesis  (ISO)
cardiac left ventricle morphogenesis  (ISO)
cartilage development  (ISO)
cell proliferation involved in endocardial cushion morphogenesis  (ISO)
cellular response to growth factor stimulus  (IBA)
common-partner SMAD protein phosphorylation  (IDA)
digestive tract development  (IEP)
embryo implantation  (IEP)
embryonic cranial skeleton morphogenesis  (ISO)
embryonic hemopoiesis  (ISO)
endocardial cushion fusion  (ISO)
gastrulation  (ISO)
growth plate cartilage chondrocyte growth  (ISO)
growth plate cartilage development  (ISO)
heart development  (IBA,ISO)
heart looping  (ISO)
in utero embryonic development  (ISO)
inferior endocardial cushion morphogenesis  (ISO)
Langerhans cell differentiation  (IEA,ISO)
lens development in camera-type eye  (ISO)
lens fiber cell apoptotic process  (ISO)
lung development  (IEP,ISO)
lung lobe morphogenesis  (ISO)
lung morphogenesis  (ISO)
mammary gland morphogenesis  (ISO)
membranous septum morphogenesis  (ISO)
miRNA transport  (ISO)
myeloid dendritic cell differentiation  (ISO)
negative regulation of cardiac muscle cell proliferation  (IMP)
negative regulation of cell population proliferation  (IGI,IMP)
Notch signaling pathway  (ISO)
outflow tract morphogenesis  (ISO)
outflow tract septum morphogenesis  (ISO)
pathway-restricted SMAD protein phosphorylation  (ISO)
peptidyl-serine phosphorylation  (ISO)
peptidyl-threonine phosphorylation  (ISO)
positive regulation of angiogenesis  (ISO)
positive regulation of B cell tolerance induction  (ISO)
positive regulation of CD4-positive, alpha-beta T cell proliferation  (ISO)
positive regulation of epithelial cell migration  (ISO)
positive regulation of epithelial to mesenchymal transition  (ISO)
positive regulation of epithelial to mesenchymal transition involved in endocardial cushion formation  (ISO)
positive regulation of mesenchymal cell proliferation  (ISO)
positive regulation of NK T cell differentiation  (ISO)
positive regulation of pathway-restricted SMAD protein phosphorylation  (ISO)
positive regulation of reactive oxygen species metabolic process  (ISO)
positive regulation of skeletal muscle tissue regeneration  (IEP)
positive regulation of smooth muscle cell proliferation  (IMP)
positive regulation of T cell tolerance induction  (ISO)
positive regulation of tolerance induction to self antigen  (ISO)
protein phosphorylation  (IBA,ISO)
receptor-mediated endocytosis  (IDA)
regulation of cell population proliferation  (ISO)
regulation of gene expression  (ISO)
regulation of stem cell proliferation  (IEA,ISO)
response to cholesterol  (ISO)
response to estrogen  (IEP)
response to glucose  (IEP)
response to hypoxia  (IEP,TAS)
response to mechanical stimulus  (IEP)
response to nutrient  (IEP)
response to organic cyclic compound  (IEP)
response to organic substance  (IEP)
response to steroid hormone  (IEP)
response to xenobiotic stimulus  (ISO)
secondary palate development  (ISO)
smoothened signaling pathway  (ISO)
superior endocardial cushion morphogenesis  (ISO)
trachea formation  (ISO)
trachea morphogenesis  (ISO)
transforming growth factor beta receptor signaling pathway  (IBA,IMP,ISO,TAS)
tricuspid valve morphogenesis  (ISO)
vasculogenesis  (IEP,ISO)
ventricular septum morphogenesis  (ISO)
wound healing  (IEP)

References

References - curated
# Reference Title Reference Citation
1. Molecular mechanisms of TGF beta receptor-triggered signaling cascades rapidly induced by the calcineurin inhibitors cyclosporin A and FK506. Akool el-S, etal., J Immunol. 2008 Aug 15;181(4):2831-45.
2. Neurogenic niche modulation by activated microglia: transforming growth factor beta increases neurogenesis in the adult dentate gyrus. Battista D, etal., Eur J Neurosci. 2006 Jan;23(1):83-93.
3. Comparison of expression of TGF-beta1, its receptors TGFbeta1R-I and TGFbeta1R-II in rat kidneys during chronic nephropathy induced by cyclosporine and tacrolimus. Bing P, etal., Transplant Proc. 2006 Sep;38(7):2180-2.
4. Down-modulation of lung immune responses by interleukin-10 and transforming growth factor beta (TGF-beta) and analysis of TGF-beta receptors I and II in active tuberculosis. Bonecini-Almeida MG, etal., Infect Immun. 2004 May;72(5):2628-34.
5. Prognostic significance of transforming growth factor beta receptor II in estrogen receptor-negative breast cancer patients. Buck MB, etal., Clin Cancer Res. 2004 Jan 15;10(2):491-8.
6. Acetaldehyde stimulates the activation of latent transforming growth factor-beta1 and induces expression of the type II receptor of the cytokine in rat cultured hepatic stellate cells. Chen A Biochem J 2002 Dec 15;368(Pt 3):683-93.
7. Cholesterol suppresses cellular TGF-beta responsiveness: implications in atherogenesis. Chen CL, etal., J Cell Sci. 2007 Oct 15;120(Pt 20):3509-21. Epub 2007 Sep 18.
8. Genomic profiling identifies alterations in TGFbeta signaling through loss of TGFbeta receptor expression in human renal cell carcinogenesis and progression. Copland JA, etal., Oncogene. 2003 Sep 11;22(39):8053-62.
9. Ontogenic expression of TGFbeta 1, 2, and 3 and its receptors in the rat gastric mucosa. de Andrade Sa ER, etal., Dev Dyn. 2003 Jul;227(3):450-7.
10. Bone marrow derived-mesenchymal stem cells downregulate IL17A dependent IL6/STAT3 signaling pathway in CCl4-induced rat liver fibrosis. Farouk S, etal., PLoS One. 2018 Oct 22;13(10):e0206130. doi: 10.1371/journal.pone.0206130. eCollection 2018.
11. Expression of transforming growth factor-beta receptors types II and III within various cells in the rat periodontium. Gao J, etal., J Periodontal Res. 1999 Feb;34(2):113-22.
12. Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium. Gaudet P, etal., Brief Bioinform. 2011 Sep;12(5):449-62. doi: 10.1093/bib/bbr042. Epub 2011 Aug 27.
13. Rat ISS GO annotations from GOA human gene data--August 2006 GOA data from the GO Consortium
14. Genetic alterations of the transforming growth factor beta receptor genes in pancreatic and biliary adenocarcinomas. Goggins M, etal., Cancer Res. 1998 Dec 1;58(23):5329-32.
15. Role of transforming growth factor-beta superfamily signaling pathways in human disease. Gordon KJ and Blobe GC, Biochim Biophys Acta. 2008 Apr;1782(4):197-228. Epub 2008 Feb 11.
16. [Detection of the expression of Smad4, transforming growth factor beta(1) and beta receptor II proteins in paraffin-embedded human pancreatic cancer tissues] Gu L, etal., Zhonghua Bing Li Xue Za Zhi. 2001 Dec;30(6):439-42.
17. [The expression of transforming growth factor beta1 and its I, II receptors in the development of rat embryo and embryonic lung] Guo Q, etal., Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2007 Apr;23(4):317-9.
18. Elevation of expression of Smads 2, 3, and 4, decorin and TGF-beta in the chronic phase of myocardial infarct scar healing. Hao J, etal., J Mol Cell Cardiol. 1999 Mar;31(3):667-78.
19. Dynamic expression patterns of transforming growth factor-beta(2) and transforming growth factor-beta receptors in experimental glomerulonephritis. Hartner A, etal., J Mol Med. 2003 Jan;81(1):32-42. Epub 2002 Dec 14.
20. Angiotensin converting enzyme inhibitor suppresses glomerular transforming growth factor beta receptor expression in experimental diabetes in rats. Hill C, etal., Diabetologia 2001 Apr;44(4):495-500.
21. Vascular proliferation and transforming growth factor-beta expression in pre- and early stage of diabetes mellitus in Otsuka Long-Evans Tokushima fatty rats. Hosomi N, etal., Atherosclerosis. 2002 May;162(1):69-76.
22. Aggressive pancreatic ductal adenocarcinoma in mice caused by pancreas-specific blockade of transforming growth factor-beta signaling in cooperation with active Kras expression. Ijichi H, etal., Genes Dev. 2006 Nov 15;20(22):3147-60.
23. Mammalian transforming growth factor-betas: Smad signaling and physio-pathological roles. Javelaud D and Mauviel A, Int J Biochem Cell Biol. 2004 Jul;36(7):1161-5.
24. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Jones S, etal., Science. 2008 Sep 26;321(5897):1801-6. Epub 2008 Sep 4.
25. Transforming growth factor-beta 1, 2, 3 and receptor type I and II in diabetic foot ulcers. Jude EB, etal., Diabet Med. 2002 Jun;19(6):440-7.
26. Loss of activin receptor type 2 protein expression in microsatellite unstable colon cancers. Jung B, etal., Gastroenterology. 2004 Mar;126(3):654-9.
27. Effects of anti-TGF-beta type II receptor antibody on experimental glomerulonephritis. Kasuga H, etal., Kidney Int. 2001 Nov;60(5):1745-55.
28. Differential expression of transforming growth factor-beta type I and II receptors by pulmonary cells in bleomycin-induced lung injury: correlation with repair and fibrosis. Khalil N, etal., Exp Lung Res. 2002 Apr-May;28(3):233-50.
29. Estrogen induces apoptosis in a rat prostatic adenocarcinoma: association with an increased expression of TGF-beta 1 and its type-I and type-II receptors. Landstrom M, etal., Int J Cancer. 1996 Aug 7;67(4):573-9.
30. Effects of hypoxia on expression of transforming growth factor-beta1 and its receptors I and II in the amoeboid microglial cells and murine BV-2 cells. Li JJ, etal., Neuroscience. 2008 Oct 15;156(3):662-72. Epub 2008 Aug 6.
31. Gene expression of transforming growth factor-beta receptors types I and II in rat endometrium during the estrous cycle and early pregnancy. Lin HY, etal., Life Sci. 2006 May 1;78(23):2669-75. Epub 2006 Jan 19.
32. TGF-beta type II receptor in rat renal vascular development: localization to juxtaglomerular cells. Liu A and Ballermann BJ, Kidney Int. 1998 Mar;53(3):716-25.
33. Transforming growth factor beta2, but not beta1 and beta3, is critical for early rat lung branching. Liu J, etal., Dev Dyn. 2000 Apr;217(4):343-60.
34. A syndrome of altered cardiovascular, craniofacial, neurocognitive and skeletal development caused by mutations in TGFBR1 or TGFBR2. Loeys BL, etal., Nat Genet. 2005 Mar;37(3):275-81. Epub 2005 Jan 30.
35. Betaglycan can act as a dual modulator of TGF-beta access to signaling receptors: mapping of ligand binding and GAG attachment sites. Lopez-Casillas F, etal., J Cell Biol. 1994 Feb;124(4):557-68.
36. SMAD pathway mediation of BDNF and TGF beta 2 regulation of proliferation and differentiation of hippocampal granule neurons. Lu J, etal., Development. 2005 Jul;132(14):3231-42. Epub 2005 Jun 15.
37. In situ detection of TGF betas, TGF beta receptor II mRNA and telomerase activity in rat cholangiocarcinogenesis. Lu JP, etal., World J Gastroenterol 2003 Mar;9(3):590-4.
38. Genomic structure of the transforming growth factor beta type II receptor gene and its mutations in hereditary nonpolyposis colorectal cancers. Lu SL, etal., Cancer Res. 1996 Oct 15;56(20):4595-8.
39. Presence of two signaling TGF-beta receptors in human pancreatic cancer correlates with advanced tumor stage. Lu Z, etal., Dig Dis Sci. 1997 Oct;42(10):2054-63.
40. Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. Markowitz S, etal., Science. 1995 Jun 2;268(5215):1336-8.
41. TGFbeta in Cancer. Massagué J, Cell. 2008 Jul 25;134(2):215-30. doi: 10.1016/j.cell.2008.07.001.
42. Expression and functional analysis of endoglin in isolated liver cells and its involvement in fibrogenic Smad signalling. Meurer SK, etal., Cell Signal. 2011 Apr;23(4):683-99. doi: 10.1016/j.cellsig.2010.12.002. Epub 2010 Dec 10.
43. Rat ISS GO annotations from MGI mouse gene data--August 2006 MGD data from the GO Consortium
44. Heterozygous TGFBR2 mutations in Marfan syndrome. Mizuguchi T, etal., Nat Genet. 2004 Aug;36(8):855-60. Epub 2004 Jul 4.
45. Effects of retinoids on the TGF-beta system and extracellular matrix in experimental glomerulonephritis. Morath C, etal., J Am Soc Nephrol. 2001 Nov;12(11):2300-9.
46. The effect of streptozotocin-induced diabetes on the rat seminal vesicle: A possible pathophysiological basis for disorders of ejaculation. Morrison JF, etal., Ann N Y Acad Sci. 2006 Nov;1084:267-79.
47. Dynamic expression of transforming growth factor-betas (TGF-beta) and their type I and type II receptors in the synovial tissue of arthritic rats. Mussener A, etal., Clin Exp Immunol. 1997 Jan;107(1):112-9.
48. Electronic Transfer of LocusLink and RefSeq Data NCBI rat LocusLink and RefSeq merged data July 26, 2002
49. Changes in TGF-beta receptors of rat hepatocytes during primary culture and liver regeneration: increased expression of TGF-beta receptors associated with increased sensitivity to TGF-beta-mediated growth inhibition. Nishikawa Y, etal., J Cell Physiol. 1998 Sep;176(3):612-23.
50. OMIM Disease Annotation Pipeline OMIM Disease Annotation Pipeline
51. Combination gene therapy of HGF and truncated type II TGF-beta receptor for rat liver cirrhosis after partial hepatectomy. Ozawa S, etal., Surgery. 2006 Apr;139(4):563-73.
52. Mutations in transforming growth factor-beta receptor type II cause familial thoracic aortic aneurysms and dissections. Pannu H, etal., Circulation. 2005 Jul 26;112(4):513-20. Epub 2005 Jul 18.
53. Expressions of transforming growth factor (TGF)-beta1 and TGF-beta type II receptor and their relationship with apoptosis during chemical hepatocarcinogenesis in rats. Park DY, etal., Hepatol Res. 2003 Nov;27(3):205-213.
54. Effect of transforming growth factor beta-1 in endotoxin-induced uveitis. Peng B, etal., Invest Ophthalmol Vis Sci. 1997 Jan;38(1):257-60.
55. Significant expression of endoglin (CD105), TGFbeta-1 and TGFbeta R-2 in the atherosclerotic aorta: an immunohistological study. Piao M and Tokunaga O, J Atheroscler Thromb. 2006 Apr;13(2):82-9.
56. KEGG Annotation Import Pipeline Pipeline to import KEGG annotations from KEGG into RGD
57. PID Annotation Import Pipeline Pipeline to import Pathway Interaction Database annotations from NCI into RGD
58. Soluble TGFbeta type II receptor gene therapy ameliorates acute radiation-induced pulmonary injury in rats. Rabbani ZN, etal., Int J Radiat Oncol Biol Phys. 2003 Oct 1;57(2):563-72.
59. GOA pipeline RGD automated data pipeline
60. ClinVar Automated Import and Annotation Pipeline RGD automated import pipeline for ClinVar variants, variant-to-disease annotations and gene-to-disease annotations
61. Data Import for Chemical-Gene Interactions RGD automated import pipeline for gene-chemical interactions
62. TGF-beta receptor expression and binding in rat mesangial cells: modulation by glucose and cyclic mechanical strain. Riser BL, etal., Kidney Int. 1999 Aug;56(2):428-39.
63. Expression of cavernous transforming growth factor-beta1 and its type II receptor in patients with erectile dysfunction. Ryu JK, etal., Int J Androl. 2004 Feb;27(1):42-9.
64. The adaptive response of transforming growth factor-beta 2 and -beta RII in the overloaded, regenerating and denervated muscles of rats. Sakuma K, etal., Acta Neuropathol (Berl). 2000 Feb;99(2):177-85.
65. Dopamine, dopamine D2 receptor short isoform, transforming growth factor (TGF)-beta1, and TGF-beta type II receptor interact to inhibit the growth of pituitary lactotropes. Sarkar DK, etal., Endocrinology. 2005 Oct;146(10):4179-88. Epub 2005 Jun 16.
66. DNA microarray analysis of pulmonary fibrosis three months after exposure to paraquat in rats. Satomi Y, etal., J Toxicol Sci. 2006 Oct;31(4):345-55.
67. Inhibition of TGFbeta signaling potentiates the FGF-2-induced stimulation of cardiomyocyte DNA synthesis. Sheikh F, etal., Cardiovasc Res. 2004 Dec 1;64(3):516-25.
68. Albumin endocytosis in endothelial cells induces TGF-beta receptor II signaling. Siddiqui SS, etal., Am J Physiol Lung Cell Mol Physiol. 2004 May;286(5):L1016-26. Epub 2004 Jan 16.
69. Transforming growth factor beta signaling impairs Neu-induced mammary tumorigenesis while promoting pulmonary metastasis. Siegel PM, etal., Proc Natl Acad Sci U S A 2003 Jul 8;100(14):8430-5. Epub 2003 Jun 13.
70. Transforming growth factor beta type II receptor expression in gastric cancer: evidence for two independent subgroups. Takeno S, etal., Anticancer Res. 2002 Jul-Aug;22(4):2247-52.
71. A dominant negative mutation of transforming growth factor-beta receptor type II gene in microsatellite stable oesophageal carcinoma. Tanaka S, etal., Br J Cancer. 2000 May;82(9):1557-60.
72. Tentative Sequence Identification Numbers Tentative Sequence Data IDs. TIGR Gene Index, Rat Data
73. Molecular characterization of rat transforming growth factor-beta type II receptor. Tsuchida K, etal., Biochem Biophys Res Commun 1993 Mar 31;191(3):790-5.
74. Regulation of TGF-beta ligand and receptor expression in neonatal rat lungs exposed to chronic hypoxia. Vicencio AG, etal., J Appl Physiol 2002 Sep;93(3):1123-30.
75. Enhanced expression of the type II transforming growth factor-beta receptor is associated with decreased survival in human pancreatic cancer. Wagner M, etal., Pancreas. 1999 Nov;19(4):370-6.
76. [Effects of salvianolic acid B on expressions of TGF-beta1 and its receptors in liver of rats with dimethylnitrosamine-induced hepatic fibrosis] Wang XN, etal., Zhong Xi Yi Jie He Xue Bao. 2005 Jul;3(4):286-9.
77. Immunohistochemical expression of FGF-2, PDGF-A, VEGF and TGF beta RII in the pancreas in the course of ischemia/reperfusion-induced acute pancreatitis. Warzecha Z, etal., J Physiol Pharmacol. 2004 Dec;55(4):791-810.
78. A direct interaction between TGFbeta activated kinase 1 and the TGFbeta type II receptor: implications for TGFbeta signalling and cardiac hypertrophy. Watkins SJ, etal., Cardiovasc Res. 2006 Feb 1;69(2):432-9. Epub 2005 Dec 19.
79. Expression of transforming growth factor-beta receptor type I and type II in rat ventral prostate and Dunning R3327 PAP adenocarcinoma in response to castration and oestrogen treatment. Wikstrom P, etal., Urol Res. 1997;25(2):103-11.
80. Cell-type-specific activation of PAK2 by transforming growth factor beta independent of Smad2 and Smad3. Wilkes MC, etal., Mol Cell Biol. 2003 Dec;23(23):8878-89.
81. Pancreatic cancer: molecular pathogenesis and new therapeutic targets. Wong HH and Lemoine NR, Nat Rev Gastroenterol Hepatol. 2009 Jul;6(7):412-22. Epub 2009 Jun 9.
82. Expression of TGF beta1 genes and their receptor types I, II, and III in low- and high-grade malignancy non-Hodgkin's lymphomas. Woszczyk D, etal., Med Sci Monit. 2004 Jan;10(1):CR33-7.
83. TGF-beta signaling alterations and susceptibility to colorectal cancer. Xu Y and Pasche B, Hum Mol Genet. 2007 Apr 15;16 Spec No 1:R14-20.
84. Role of PKC and TGF-beta receptor in glucose-induced proliferation of smooth muscle cells. Yasuda Y, etal., Biochem Biophys Res Commun. 2001 Feb 16;281(1):71-7.
85. The TGF-{beta}/Smad2,3 signalling axis is impaired in experimental pulmonary hypertension. Zakrzewicz A, etal., Eur Respir J. 2007 Mar 28;.
86. Transforming growth factor-beta(s) and their receptors in aging rat prostate. Zhao H, etal., Biochem Biophys Res Commun. 2002 Jun 7;294(2):464-9.
87. Expression of transforming growth factor-beta type II receptor in rat lung is regulated during development. Zhao Y and Young SL, Am J Physiol. 1995 Sep;269(3 Pt 1):L419-26.
88. TGF-beta receptor types I and II are differentially expressed during corneal epithelial wound repair. Zieske JD, etal., Invest Ophthalmol Vis Sci. 2001 Jun;42(7):1465-71.
Additional References at PubMed
PMID:1326540   PMID:1333888   PMID:7852346   PMID:8264154   PMID:8774881   PMID:10030593   PMID:11157754   PMID:11641223   PMID:12015308   PMID:12459253   PMID:12773577   PMID:12975342  
PMID:15578192   PMID:15781643   PMID:16332365   PMID:16611331   PMID:16690877   PMID:16806156   PMID:16897002   PMID:16973387   PMID:17050629   PMID:17078885   PMID:17164348   PMID:17471240  
PMID:17533113   PMID:17938236   PMID:17953362   PMID:17972267   PMID:18243111   PMID:18381416   PMID:18453574   PMID:18498113   PMID:18990706   PMID:20039857   PMID:20160708   PMID:20652948  
PMID:21378033   PMID:21382347   PMID:21420963   PMID:22425884   PMID:22964853   PMID:23486519   PMID:23868260   PMID:25178280   PMID:25446530   PMID:25801897   PMID:25813266   PMID:25893292  
PMID:26284552   PMID:26362850   PMID:26459119   PMID:26788514   PMID:29196166   PMID:30468668   PMID:31147562   PMID:31315051  


Genomics

Comparative Map Data
Tgfbr2
(Rattus norvegicus - Norway rat)
Rat AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
mRatBN7.28115,794,537 - 115,883,615 (-)NCBImRatBN7.2
mRatBN7.2 Ensembl8115,794,537 - 115,883,228 (-)Ensembl
Rnor_6.08124,310,288 - 124,399,345 (-)NCBIRnor6.0Rnor_6.0rn6Rnor6.0
Rnor_6.0 Ensembl8124,312,754 - 124,399,494 (-)EnsemblRnor6.0rn6Rnor6.0
Rnor_5.08123,585,765 - 123,671,209 (-)NCBIRnor5.0Rnor_5.0rn5Rnor5.0
RGSC_v3.48120,593,595 - 120,680,453 (-)NCBIRGSC3.4rn4RGSC3.4
RGSC_v3.18120,613,331 - 120,700,190 (-)NCBI
Celera8115,012,175 - 115,096,500 (-)NCBICelera
Cytogenetic Map8q32NCBI
TGFBR2
(Homo sapiens - human)
Human AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
GRCh38330,606,356 - 30,694,142 (+)NCBIGRCh38GRCh38hg38GRCh38
GRCh38.p13 Ensembl330,606,601 - 30,694,142 (+)EnsemblGRCh38hg38GRCh38
GRCh37330,647,994 - 30,735,634 (+)NCBIGRCh37GRCh37hg19GRCh37
Build 36330,622,998 - 30,710,638 (+)NCBINCBI36hg18NCBI36
Build 34330,623,041 - 30,708,147NCBI
Celera330,584,920 - 30,672,564 (+)NCBI
Cytogenetic Map3p24.1NCBI
HuRef330,590,599 - 30,678,240 (+)NCBIHuRef
CHM1_1330,598,177 - 30,685,783 (+)NCBICHM1_1
T2T-CHM13v2.0330,609,008 - 30,696,629 (+)NCBI
Tgfbr2
(Mus musculus - house mouse)
Mouse AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
GRCm399115,916,763 - 116,004,431 (-)NCBIGRCm39mm39
GRCm39 Ensembl9115,913,361 - 116,004,428 (-)Ensembl
GRCm389116,087,695 - 116,175,363 (-)NCBIGRCm38GRCm38mm10GRCm38
GRCm38.p6 Ensembl9116,084,293 - 116,175,360 (-)EnsemblGRCm38mm10GRCm38
MGSCv379115,996,813 - 116,084,481 (-)NCBIGRCm37mm9NCBIm37
MGSCv369115,936,405 - 116,023,987 (-)NCBImm8
Celera9116,548,860 - 116,637,499 (-)NCBICelera
Cytogenetic Map9F3NCBI
cM Map968.39NCBI
Tgfbr2
(Chinchilla lanigera - long-tailed chinchilla)
Chinchilla AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
ChiLan1.0 EnsemblNW_00495543021,932,553 - 22,001,837 (+)EnsemblChiLan1.0
ChiLan1.0NW_00495543021,919,338 - 21,999,688 (+)NCBIChiLan1.0ChiLan1.0
TGFBR2
(Pan paniscus - bonobo/pygmy chimpanzee)
Bonobo AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
PanPan1.1330,854,071 - 30,941,378 (+)NCBIpanpan1.1PanPan1.1panPan2
PanPan1.1 Ensembl330,854,460 - 30,938,856 (+)Ensemblpanpan1.1panPan2
Mhudiblu_PPA_v0330,536,187 - 30,623,653 (+)NCBIMhudiblu_PPA_v0panPan3
TGFBR2
(Canis lupus familiaris - dog)
Dog AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
CanFam3.12313,886,869 - 13,946,480 (-)NCBICanFam3.1CanFam3.1canFam3CanFam3.1
CanFam3.1 Ensembl2313,889,000 - 13,977,636 (-)EnsemblCanFam3.1canFam3CanFam3.1
Dog10K_Boxer_Tasha2313,869,985 - 13,959,686 (-)NCBI
ROS_Cfam_1.02314,182,445 - 14,272,114 (-)NCBI
ROS_Cfam_1.0 Ensembl2314,182,447 - 14,272,161 (-)Ensembl
UMICH_Zoey_3.12313,979,792 - 14,069,422 (-)NCBI
UNSW_CanFamBas_1.02314,125,731 - 14,215,435 (-)NCBI
UU_Cfam_GSD_1.02314,144,194 - 14,234,152 (-)NCBI
Tgfbr2
(Ictidomys tridecemlineatus - thirteen-lined ground squirrel)
Squirrel AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
HiC_Itri_2NW_024405118188,186,107 - 188,270,859 (+)NCBI
SpeTri2.0NW_00493647321,324,669 - 21,409,430 (+)NCBISpeTri2.0SpeTri2.0SpeTri2.0
TGFBR2
(Sus scrofa - pig)
Pig AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
Sscrofa11.1 Ensembl1316,784,491 - 16,878,165 (+)EnsemblSscrofa11.1susScr11Sscrofa11.1
Sscrofa11.11316,784,370 - 16,875,828 (+)NCBISscrofa11.1Sscrofa11.1susScr11Sscrofa11.1
Sscrofa10.21318,707,787 - 18,712,636 (-)NCBISscrofa10.2Sscrofa10.2susScr3
TGFBR2
(Chlorocebus sabaeus - green monkey)
Green Monkey AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
ChlSab1.11575,112,903 - 75,200,263 (+)NCBIChlSab1.1chlSab2
ChlSab1.1 Ensembl1575,112,561 - 75,197,711 (+)EnsemblChlSab1.1chlSab2
Vero_WHO_p1.0NW_02366604148,399,611 - 48,486,893 (+)NCBIVero_WHO_p1.0
Tgfbr2
(Heterocephalus glaber - naked mole-rat)
Naked Mole-rat AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
HetGla_female_1.0 EnsemblNW_0046247888,447,542 - 8,535,959 (+)EnsemblHetGla_female_1.0hetGla2
HetGla 1.0NW_0046247888,447,679 - 8,535,821 (+)NCBIHetGla_female_1.0hetGla2

Position Markers
D8Got214  
Rat AssemblyChrPosition (strand)SourceJBrowse
mRatBN7.28115,876,703 - 115,876,983 (+)MAPPERmRatBN7.2
Rnor_6.08124,392,370 - 124,392,649NCBIRnor6.0
Rnor_5.08123,664,527 - 123,664,806UniSTSRnor5.0
RGSC_v3.48120,673,910 - 120,674,190RGDRGSC3.4
RGSC_v3.48120,673,911 - 120,674,190UniSTSRGSC3.4
RGSC_v3.18120,693,647 - 120,693,927RGD
Celera8115,089,982 - 115,090,261UniSTS
RH 3.4 Map81222.2UniSTS
RH 3.4 Map81222.2RGD
RH 2.0 Map8979.3RGD
Cytogenetic Map8q32UniSTS
AI715297  
Rat AssemblyChrPosition (strand)SourceJBrowse
mRatBN7.28115,796,930 - 115,797,071 (+)MAPPERmRatBN7.2
Rnor_6.08124,312,682 - 124,312,822NCBIRnor6.0
Rnor_5.08123,585,618 - 123,585,758UniSTSRnor5.0
RGSC_v3.48120,593,448 - 120,593,588UniSTSRGSC3.4
Celera8115,012,028 - 115,012,168UniSTS
RH 3.4 Map81230.2UniSTS
Cytogenetic Map8q32UniSTS


QTLs in Region (mRatBN7.2)
The following QTLs overlap with this region.    Full Report CSV TAB Printer Gviewer
RGD IDSymbolNameLODP ValueTraitSub TraitChrStartStopSpecies
1554321Bmd3Bone mineral density QTL 37.90.0001femur mineral mass (VT:0010011)volumetric bone mineral density (CMO:0001553)840952565123900184Rat
70197BpQTLcluster8Blood pressure QTL cluster 83.482arterial blood pressure trait (VT:2000000)mean arterial blood pressure (CMO:0000009)846531639119088624Rat
70197BpQTLcluster8Blood pressure QTL cluster 83.482arterial blood pressure trait (VT:2000000)pulse pressure (CMO:0000292)846531639119088624Rat
70197BpQTLcluster8Blood pressure QTL cluster 83.482arterial blood pressure trait (VT:2000000)absolute change in systolic blood pressure (CMO:0000607)846531639119088624Rat
70197BpQTLcluster8Blood pressure QTL cluster 83.482arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)846531639119088624Rat
2303171Bp331Blood pressure QTL 3315.570.005arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)861290298119084929Rat
1300171Bp184Blood pressure QTL 1843.66arterial blood pressure trait (VT:2000000)blood pressure time series experimental set point of the baroreceptor response (CMO:0002593)870513503118219066Rat
8694446Bw170Body weight QTL 17012.070.001retroperitoneal fat pad mass (VT:0010430)retroperitoneal fat pad weight to body weight ratio (CMO:0000635)871888757116888757Rat
9590292Uminl3Urine mineral level QTL 33.620.001urine mineral amount (VT:0015086)urine electrolyte level (CMO:0000593)871888757116888757Rat
8694200Abfw4Abdominal fat weight QTL 49.070.001visceral adipose mass (VT:0010063)abdominal fat pad weight to body weight ratio (CMO:0000095)871888757116888757Rat
8694392Bw161Body weight QTL 1618.060.001body lean mass (VT:0010483)lean tissue morphological measurement (CMO:0002184)871888757116888757Rat
1549909Stresp11Stress response QTL 116.830.0019stress-related behavior trait (VT:0010451)number of approaches toward negative stimulus before onset of defensive burying response (CMO:0001960)873473045118473045Rat
2300181Bmd55Bone mineral density QTL 555.70.0001femur mineral mass (VT:0010011)volumetric bone mineral density (CMO:0001553)876468691121468691Rat
61437Cia6Collagen induced arthritis QTL 6joint integrity trait (VT:0010548)joint inflammation composite score (CMO:0000919)882460758122812818Rat
738011Anxrr9Anxiety related response QTL 96.1exploratory behavior trait (VT:0010471)number of entries into a discrete space in an experimental apparatus (CMO:0000960)893535351123900184Rat
1358893Bp263Blood pressure QTL 2635.01arterial blood pressure trait (VT:2000000)mean arterial blood pressure (CMO:0000009)893965141123900184Rat
1358903Bp252Blood pressure QTL 25270.0001arterial blood pressure trait (VT:2000000)mean arterial blood pressure (CMO:0000009)893965141123900184Rat
738014Anxrr15Anxiety related response QTL 153.60.005locomotor behavior trait (VT:0001392)amount of experiment time spent in a discrete space in an experimental apparatus (CMO:0000958)895718998123900184Rat
2300182Bmd56Bone mineral density QTL 565.4femur mineral mass (VT:0010011)volumetric bone mineral density (CMO:0001553)895718998123900184Rat
724539Cm19Cardiac mass QTL 192.6heart mass (VT:0007028)calculated heart weight (CMO:0000073)8100149864120994388Rat
1599689Iddm24Insulin dependent diabetes mellitus QTL 244.720.001blood glucose amount (VT:0000188)age at onset/diagnosis of type 1 diabetes mellitus (CMO:0001140)8112834440118649220Rat


Genetic Models
This gene Tgfbr2 is modified in the following models/strains
miRNA Target Status

Predicted Target Of
Summary Value
Count of predictions:47
Count of miRNA genes:36
Interacting mature miRNAs:42
Transcripts:ENSRNOT00000037883
Prediction methods:Miranda, Rnahybrid, Targetscan
Result types:miRGate_prediction

The detailed report is available here: Full Report CSV TAB Printer

miRNA Target Status data imported from miRGate (http://mirgate.bioinfo.cnio.es/).
For more information about miRGate, see PMID:25858286 or access the full paper here.


Expression


RNA-SEQ Expression
High: > 1000 TPM value   Medium: Between 11 and 1000 TPM
Low: Between 0.5 and 10 TPM   Below Cutoff: < 0.5 TPM

alimentary part of gastrointestinal system circulatory system endocrine system exocrine system hemolymphoid system hepatobiliary system integumental system musculoskeletal system nervous system renal system reproductive system respiratory system appendage
High
Medium 3 42 57 41 19 41 8 11 31 35 34 11 8
Low 1 43 7
Below cutoff

Sequence


Reference Sequences
RefSeq Acc Id: ENSRNOT00000037883   ⟹   ENSRNOP00000035501
RefSeq Status:
Type: CODING
Position:
Rat AssemblyChrPosition (strand)Source
mRatBN7.2 Ensembl8115,794,537 - 115,882,987 (-)Ensembl
Rnor_6.0 Ensembl8124,312,754 - 124,399,494 (-)Ensembl
RefSeq Acc Id: ENSRNOT00000116107   ⟹   ENSRNOP00000093892
RefSeq Status:
Type: CODING
Position:
Rat AssemblyChrPosition (strand)Source
mRatBN7.2 Ensembl8115,794,537 - 115,883,228 (-)Ensembl
RefSeq Acc Id: NM_031132   ⟹   NP_112394
RefSeq Status: VALIDATED
Type: CODING
Position:
Rat AssemblyChrPosition (strand)Source
mRatBN7.28115,796,846 - 115,883,343 (-)NCBI
Rnor_6.08124,312,829 - 124,398,864 (-)NCBI
Rnor_5.08123,585,765 - 123,671,209 (-)NCBI
RGSC_v3.48120,593,595 - 120,680,453 (-)RGD
Celera8115,012,175 - 115,096,500 (-)RGD
Sequence:
RefSeq Acc Id: XM_008766690   ⟹   XP_008764912
RefSeq Status:
Type: CODING
Position:
Rat AssemblyChrPosition (strand)Source
mRatBN7.28115,794,537 - 115,883,615 (-)NCBI
Rnor_6.08124,310,288 - 124,399,345 (-)NCBI
Sequence:
Reference Sequences
RefSeq Acc Id: NP_112394   ⟸   NM_031132
- Peptide Label: precursor
- Sequence:
RefSeq Acc Id: XP_008764912   ⟸   XM_008766690
- Peptide Label: isoform X1
- Sequence:
RefSeq Acc Id: ENSRNOP00000035501   ⟸   ENSRNOT00000037883
RefSeq Acc Id: ENSRNOP00000093892   ⟸   ENSRNOT00000116107
Protein Domains
Protein kinase

Protein Structures
Name Modeler Protein Id AA Range Protein Structure
AF-P38438-F1-model_v2 AlphaFold P38438 1-567 view protein structure

Transcriptome

eQTL   View at Phenogen
WGCNA   View at Phenogen
Tissue/Strain Expression   View at Phenogen

Promoters
RGD ID:13696359
Promoter ID:EPDNEW_R6884
Type:initiation region
Name:Tgfbr2_1
Description:transforming growth factor, beta receptor 2
SO ACC ID:SO:0000170
Source:EPDNEW (Eukaryotic Promoter Database, http://epd.vital-it.ch/)
Experiment Methods:Single-end sequencing.
Position:
Rat AssemblyChrPosition (strand)Source
Rnor_6.08124,398,828 - 124,398,888EPDNEW

Strain Variation

Strain Sequence Variants (MRatBN7.2)
ACI/EurMcwi (2019)
Visual CSV TAB Printer
Platform: GSPMC-Illumina-NovaSeq6000
Secondary Analysis: BWA_mem_v.0.7.17,_GATK_v.4.1.3.0
Breeder: MCW
Description: Dr. Mindy Dwinell - Hybrid rat diversity program
ACI/N (2020)
Visual CSV TAB Printer
Platform: GSPMC-Illumina-NovaSeq6000
Secondary Analysis: BWA_mem_v.0.7.17,_GATK_v.4.1.3.0
Breeder: NIH
Description: Dr. Mindy Dwinell - Hybrid rat diversity program
BN-Lx/CubMcwi (2019)
Visual CSV TAB Printer
Platform: GSPMC-Illumina-NovaSeq6000
Secondary Analysis: BWA_mem_v.0.7.17,_GATK_v.4.1.3.0
Breeder: MCW
Description: Dr. Mindy Dwinell - Hybrid rat diversity program
BN/NHsdMcwi (2019)
Visual CSV TAB Printer
Platform: GSPMC-Illumina-NovaSeq6000
Secondary Analysis: BWA_mem_v.0.7.17,_GATK_v.4.1.3.0
Breeder: MCW
Description: Dr. Mindy Dwinell - Hybrid rat diversity program
BN/NHsdMcwi (2020)
Visual CSV TAB Printer
Platform: GSPMC-Illumina-NovaSeq6000
Secondary Analysis: BWA_mem_v.0.7.17,_GATK_v.4.1.3.0
Breeder: MCW
Description: Dr. Mindy Dwinell - Hybrid rat diversity program
BN/SsN (2020)
Visual CSV TAB Printer
Platform: GSPMC-Illumina-NovaSeq6000
Secondary Analysis: BWA_mem_v.0.7.17,_GATK_v.4.1.3.0
Breeder: NIH
Description: Dr. Mindy Dwinell - Hybrid rat diversity program
BUF/N (2020)
Visual CSV TAB Printer
Platform: GSPMC-Illumina-NovaSeq6000
Secondary Analysis: BWA_mem_v.0.7.17,_GATK_v.4.1.3.0
Breeder: NIH
Description: Dr. Mindy Dwinell - Hybrid rat diversity program
BXH2/CubMcwi (2020)
Visual CSV TAB Printer
Platform: GSPMC-Illumina-NovaSeq6000
Secondary Analysis: BWA_mem_v.0.7.17,_GATK_v.4.1.3.0
Breeder: MCW
Description: Dr. Mindy Dwinell - Hybrid rat diversity program
BXH3/CubMcwi (2020)
Visual CSV TAB Printer
Platform: GSPMC-Illumina-NovaSeq6000
Secondary Analysis: BWA_mem_v.0.7.17,_GATK_v.4.1.3.0
Breeder: MCW
Description: Dr. Mindy Dwinell - Hybrid rat diversity program
DA/OlaHsd (2019)
Visual CSV TAB Printer
Platform: GSPMC-Illumina-NovaSeq6000
Secondary Analysis: BWA_mem_v.0.7.17,_GATK_v.4.1.3.0
Breeder: Envigo
Description: Dr. Mindy Dwinell - Hybrid rat diversity program
F344/DuCrl (2019)
Visual CSV TAB Printer
Platform: GSPMC-Illumina-NovaSeq6000
Secondary Analysis: BWA_mem_v.0.7.17,_GATK_v.4.1.3.0
Breeder: Charles River
Description: Dr. Mindy Dwinell - Hybrid rat diversity program
F344/N (2020)
Visual CSV TAB Printer
Platform: GSPMC-Illumina-NovaSeq6000
Secondary Analysis: BWA_mem_v.0.7.17,_GATK_v.4.1.3.0
Breeder: NIH
Description: Dr. Mindy Dwinell - Hybrid rat diversity program
F344/NCrl (2019)
Visual CSV TAB Printer
Platform: GSPMC-Illumina-NovaSeq6000
Secondary Analysis: BWA_mem_v.0.7.17,_GATK_v.4.1.3.0
Breeder: Charles River
Description: Dr. Mindy Dwinell - Hybrid rat diversity program
F344/Stm (2019)
Visual CSV TAB Printer
Platform: GSPMC-Illumina-NovaSeq6000
Secondary Analysis: BWA_mem_v.0.7.17,_GATK_v.4.1.3.0
Breeder: Japan
Description: Dr. Mindy Dwinell - Hybrid rat diversity program
FHH/EurMcwi (2019)
Visual CSV TAB Printer
Platform: GSPMC-Illumina-NovaSeq6000
Secondary Analysis: BWA_mem_v.0.7.17,_GATK_v.4.1.3.0
Breeder: MCW
Description: Dr. Mindy Dwinell - Hybrid rat diversity program
FXLE16/Stm (2020)
Visual CSV TAB Printer
Platform: GSPMC-Illumina-NovaSeq6000
Secondary Analysis: BWA_mem_v.0.7.17,_GATK_v.4.1.3.0
Breeder: Japan
Description: Dr. Mindy Dwinell - Hybrid rat diversity program
FXLE18/Stm (2020)
Visual CSV TAB Printer
Platform: GSPMC-Illumina-NovaSeq6000
Secondary Analysis: BWA_mem_v.0.7.17,_GATK_v.4.1.3.0
Breeder: Japan
Description: Dr. Mindy Dwinell - Hybrid rat diversity program
GK/FarMcwi (2019)
Visual CSV TAB Printer
Platform: GSPMC-Illumina-NovaSeq6000
Secondary Analysis: BWA_mem_v.0.7.17,_GATK_v.4.1.3.0
Breeder: MCW
Description: Dr. Mindy Dwinell - Hybrid rat diversity program
HXB10/IpcvMcwi (2019)
Visual CSV TAB Printer
Platform: GSPMC-Illumina-NovaSeq6000
Secondary Analysis: BWA_mem_v.0.7.17,_GATK_v.4.1.3.0
Breeder: MCW
Description: Dr. Mindy Dwinell - Hybrid rat diversity program
HXB2/IpcvMcwi (2019)
Visual CSV TAB Printer
Platform: GSPMC-Illumina-NovaSeq6000
Secondary Analysis: BWA_mem_v.0.7.17,_GATK_v.4.1.3.0
Breeder: MCW
Description: Dr. Mindy Dwinell - Hybrid rat diversity program
HXB20/IpcvMcwi (2020)
Visual CSV TAB Printer
Platform: GSPMC-Illumina-NovaSeq6000
Secondary Analysis: BWA_mem_v.0.7.17,_GATK_v.4.1.3.0
Breeder: MCW
Description: Dr. Mindy Dwinell - Hybrid rat diversity program
HXB31/IpcvMcwi (2019)
Visual CSV TAB Printer
Platform: GSPMC-Illumina-NovaSeq6000
Secondary Analysis: BWA_mem_v.0.7.17,_GATK_v.4.1.3.0
Breeder: MCW
Description: Dr. Mindy Dwinell - Hybrid rat diversity program
HXB4/IpcvMcwi (2020)
Visual CSV TAB Printer
Platform: GSPMC-Illumina-NovaSeq6000
Secondary Analysis: BWA_mem_v.0.7.17,_GATK_v.4.1.3.0
Breeder: MCW
Description: Dr. Mindy Dwinell - Hybrid rat diversity program
LE/Stm (2019)
Visual CSV TAB Printer
Platform: GSPMC-Illumina-NovaSeq6000
Secondary Analysis: BWA_mem_v.0.7.17,_GATK_v.4.1.3.0
Breeder: MCW
Description: Dr. Mindy Dwinell - Hybrid rat diversity program
LEW/Crl (2019)
Visual CSV TAB Printer
Platform: GSPMC-Illumina-NovaSeq6000
Secondary Analysis: BWA_mem_v.0.7.17,_GATK_v.4.1.3.0
Breeder: Charles River
Description: Dr. Mindy Dwinell - Hybrid rat diversity program
LEXF10A/StmMcwi (2020)
Visual CSV TAB Printer
Platform: GSPMC-Illumina-NovaSeq6000
Secondary Analysis: BWA_mem_v.0.7.17,_GATK_v.4.1.3.0
Breeder: MCW
Description: Dr. Mindy Dwinell - Hybrid rat diversity program
LEXF11/Stm (2020)
Visual CSV TAB Printer
Platform: GSPMC-Illumina-NovaSeq6000
Secondary Analysis: BWA_mem_v.0.7.17,_GATK_v.4.1.3.0
Breeder: Japan
Description: Dr. Mindy Dwinell - Hybrid rat diversity program
LEXF1A/Stm (2019)
Visual CSV TAB Printer
Platform: GSPMC-Illumina-NovaSeq6000
Secondary Analysis: BWA_mem_v.0.7.17,_GATK_v.4.1.3.0
Breeder: Japan
Description: Dr. Mindy Dwinell - Hybrid rat diversity program
LEXF1C/Stm (2019)
Visual CSV TAB Printer
Platform: GSPMC-Illumina-NovaSeq6000
Secondary Analysis: BWA_mem_v.0.7.17,_GATK_v.4.1.3.0
Breeder: Japan
Description: Dr. Mindy Dwinell - Hybrid rat diversity program
LEXF2B/Stm (2019)
Visual CSV TAB Printer
Platform: GSPMC-Illumina-NovaSeq6000
Secondary Analysis: BWA_mem_v.0.7.17,_GATK_v.4.1.3.0
Breeder: Japan
Description: Dr. Mindy Dwinell - Hybrid rat diversity program
LEXF3/Stm (2020)
Visual CSV TAB Printer
Platform: GSPMC-Illumina-NovaSeq6000
Secondary Analysis: BWA_mem_v.0.7.17,_GATK_v.4.1.3.0
Breeder: Japan
Description: Dr. Mindy Dwinell - Hybrid rat diversity program
LEXF4/Stm (2020)
Visual CSV TAB Printer
Platform: GSPMC-Illumina-NovaSeq6000
Secondary Analysis: BWA_mem_v.0.7.17,_GATK_v.4.1.3.0
Breeder: Japan
Description: Dr. Mindy Dwinell - Hybrid rat diversity program
LH/MavRrrcAek (2020)
Visual CSV TAB Printer
Platform: GSPMC-Illumina-NovaSeq6000
Secondary Analysis: BWA_mem_v.0.7.17,_GATK_v.4.1.3.0
Breeder: Kwitek
Description: Dr. Mindy Dwinell - Hybrid rat diversity program
LL/MavRrrcAek (2020)
Visual CSV TAB Printer
Platform: GSPMC-Illumina-NovaSeq6000
Secondary Analysis: BWA_mem_v.0.7.17,_GATK_v.4.1.3.0
Breeder: Kwitek
Description: Dr. Mindy Dwinell - Hybrid rat diversity program
LN/MavRrrcAek (2020)
Visual CSV TAB Printer
Platform: GSPMC-Illumina-NovaSeq6000
Secondary Analysis: BWA_mem_v.0.7.17,_GATK_v.4.1.3.0
Breeder: Kwitek
Description: Dr. Mindy Dwinell - Hybrid rat diversity program
M520/N (2020)
Visual CSV TAB Printer
Platform: GSPMC-Illumina-NovaSeq6000
Secondary Analysis: BWA_mem_v.0.7.17,_GATK_v.4.1.3.0
Breeder: NIH
Description: Dr. Mindy Dwinell - Hybrid rat diversity program
M520/NRrrcMcwi (2019)
Visual CSV TAB Printer
Platform: GSPMC-Illumina-NovaSeq6000
Secondary Analysis: BWA_mem_v.0.7.17,_GATK_v.4.1.3.0
Breeder: MCW
Description: Dr. Mindy Dwinell - Hybrid rat diversity program
MR/N (2020)
Visual CSV TAB Printer
Platform: GSPMC-Illumina-NovaSeq6000
Secondary Analysis: BWA_mem_v.0.7.17,_GATK_v.4.1.3.0
Breeder: NIH
Description: Dr. Mindy Dwinell - Hybrid rat diversity program
MWF/Hsd (2019)
Visual CSV TAB Printer
Platform: GSPMC-Illumina-NovaSeq6000
Secondary Analysis: BWA_mem_v.0.7.17,_GATK_v.4.1.3.0
Breeder: MCW
Description: Dr. Mindy Dwinell - Hybrid rat diversity program
PVG/Seac (2019)
Visual CSV TAB Printer
Platform: GSPMC-Illumina-NovaSeq6000
Secondary Analysis: BWA_mem_v.0.7.17,_GATK_v.4.1.3.0
Breeder: Japan
Description: Dr. Mindy Dwinell - Hybrid rat diversity program
SHR/OlalpcvMcwi (2019)
Visual CSV TAB Printer
Platform: GSPMC-Illumina-NovaSeq6000
Secondary Analysis: BWA_mem_v.0.7.17,_GATK_v.4.1.3.0
Breeder: MCW
Description: Dr. Mindy Dwinell - Hybrid rat diversity program
SHRSP/A3NCrl (2019)
Visual CSV TAB Printer
Platform: GSPMC-Illumina-NovaSeq6000
Secondary Analysis: BWA_mem_v.0.7.17,_GATK_v.4.1.3.0
Breeder: Charles River
Description: Dr. Mindy Dwinell - Hybrid rat diversity program
SR/JrHsd (2020)
Visual CSV TAB Printer
Platform: GSPMC-Illumina-NovaSeq6000
Secondary Analysis: BWA_mem_v.0.7.17,_GATK_v.4.1.3.0
Breeder: Envigo
Description: Dr. Mindy Dwinell - Hybrid rat diversity program
SS/JrHsdMcwi (2019)
Visual CSV TAB Printer
Platform: GSPMC-Illumina-NovaSeq6000
Secondary Analysis: BWA_mem_v.0.7.17,_GATK_v.4.1.3.0
Breeder: MCW
Description: Dr. Mindy Dwinell - Hybrid rat diversity program
WAG/RijCrl (2020)
Visual CSV TAB Printer
Platform: GSPMC-Illumina-NovaSeq6000
Secondary Analysis: BWA_mem_v.0.7.17,_GATK_v.4.1.3.0
Breeder: Charles River
Description: Dr. Mindy Dwinell - Hybrid rat diversity program
WKY/N (2020)
Visual CSV TAB Printer
Platform: GSPMC-Illumina-NovaSeq6000
Secondary Analysis: BWA_mem_v.0.7.17,_GATK_v.4.1.3.0
Breeder: NIH
Description: Dr. Mindy Dwinell - Hybrid rat diversity program
WKY/NCrl (2019)
Visual CSV TAB Printer
Platform: GSPMC-Illumina-NovaSeq6000
Secondary Analysis: BWA_mem_v.0.7.17,_GATK_v.4.1.3.0
Breeder: Charles River
Description: Dr. Mindy Dwinell - Hybrid rat diversity program
WN/N (2020)
Visual CSV TAB Printer
Platform: GSPMC-Illumina-NovaSeq6000
Secondary Analysis: BWA_mem_v.0.7.17,_GATK_v.4.1.3.0
Breeder: NIH
Description: Dr. Mindy Dwinell - Hybrid rat diversity program

Additional Information

Database Acc Id Source(s)
AGR Gene RGD:69651 AgrOrtholog
BioCyc Gene G2FUF-28869 BioCyc
Ensembl Genes ENSRNOG00000013265 Ensembl, ENTREZGENE, UniProtKB/Swiss-Prot
Ensembl Protein ENSRNOP00000035501 ENTREZGENE
  ENSRNOP00000093892 ENTREZGENE, UniProtKB/Swiss-Prot
Ensembl Transcript ENSRNOT00000037883 ENTREZGENE
  ENSRNOT00000116107 ENTREZGENE, UniProtKB/Swiss-Prot
Gene3D-CATH 2.10.60.10 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
InterPro Kinase-like_dom_sf UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Prot_kinase_dom UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Protein_kinase_ATP_BS UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Ser-Thr/Tyr_kinase_cat_dom UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Ser/Thr_kinase_AS UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Snake_toxin-like_sf UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  TGFB_receptor UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Transform_growth_fac-b_typ-2 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Transforming_GF_b_rcpt_2_ecto UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
KEGG Report rno:81810 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
NCBI Gene 81810 ENTREZGENE
PANTHER PTHR23255 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
Pfam ecTbetaR2 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  PK_Tyr_Ser-Thr UniProtKB/TrEMBL, UniProtKB/Swiss-Prot
PhenoGen Tgfbr2 PhenoGen
PIRSF TGFRII UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
PRINTS ACTIVIN2R UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
PROSITE PROTEIN_KINASE_ATP UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  PROTEIN_KINASE_DOM UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  PROTEIN_KINASE_ST UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
SMART S_TKc UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
Superfamily-SCOP SSF56112 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  SSF57302 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
TIGR TC206174
UniProt D0VED2_RAT UniProtKB/TrEMBL
  P38438 ENTREZGENE, UniProtKB/Swiss-Prot


Nomenclature History
Date Current Symbol Current Name Previous Symbol Previous Name Description Reference Status
2014-03-13 Tgfbr2  transforming growth factor, beta receptor 2  Tgfbr2  transforming growth factor, beta receptor II  Nomenclature updated to reflect human and mouse nomenclature 1299863 APPROVED
2008-07-01 Tgfbr2T  transforming growth factor, beta receptor IIT  Tgfbr2  transforming growth factor, beta receptor II  Nomenclature updated to reflect human and mouse nomenclature 1299863 APPROVED
2008-07-01 Tgfbr2  transforming growth factor, beta receptor II  Tgfbr2T  transforming growth factor, beta receptor IIT  Nomenclature updated to reflect human and mouse nomenclature 1299863 APPROVED
2008-06-11 Tgfbr2T  transforming growth factor, beta receptor IIT  Tgfbr2  transforming growth factor, beta receptor II  Nomenclature updated to reflect human and mouse nomenclature 1299863 APPROVED
2008-06-11 Tgfbr2  transforming growth factor, beta receptor II  Tgfbr2T  transforming growth factor, beta receptor IIT  Nomenclature updated to reflect human and mouse nomenclature 1299863 APPROVED
2002-06-10 Tgfbr2  transforming growth factor, beta receptor 2      Name updated 70584 APPROVED
2002-02-26 Tgfbr2  transforming growth factor, beta receptor II      Name updated to reflect Human and Mouse nomenclature 70292 APPROVED

RGD Curation Notes
Note Type Note Reference
gene_disease may play a role in the development of diabetic nephrepathy 68928
gene_function receptor for TGF-beta and a constitutively active serine threonine kinase 68928
gene_pathway binding TGF-beta isoform leads to recruitment and phosphorylation of Tgfbr1, starting the signaling cascade to the nucleus through the Smad proteins 68928
gene_process inhibits the synthesis of collagenases and stimulates tissue production of metalloproteinase inhibitors 68928